ARISTOCORT A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARISTOCORT A (ARISTOCORT A).
Triamcinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, suppress cytokine production, and decrease inflammation and immune responses.
| Metabolism | Triamcinolone acetonide is primarily metabolized in the liver via CYP3A4, with minor metabolism by other CYP enzymes. Metabolites are inactive. |
| Excretion | Renal: 75% as metabolites (primarily conjugated), 15% as unchanged drug. Biliary/fecal: 10%. |
| Half-life | Terminal half-life: 2-3 hours for triamcinolone acetonide. Clinical context: Duration of action longer due to receptor binding and intracellular activity; anti-inflammatory effects persist 24-48 hours after IM administration. |
| Protein binding | 68-78% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Vd: 0.8-1.2 L/kg. Clinical meaning: Indicates extensive tissue distribution, including synovial fluid and skin. |
| Bioavailability | Intramuscular: 100% (depot preparation). Topical: 0.5-1% systemically absorbed from intact skin; higher with occlusion or inflamed skin. Oral: Not applicable (not available orally in this formulation). |
| Onset of Action | Intramuscular: 24-48 hours. Intra-articular/soft tissue: 12-24 hours. Topical: Variable, typically 3-5 days for dermatologic effects. |
| Duration of Action | Intramuscular: 1-4 weeks (depot effect). Intra-articular: 1-2 weeks. Topical: 1-2 weeks with occlusive dressing. Clinical notes: Duration is prolonged due to slow release from injection site and high receptor affinity. |
Intralesional injection: 2.5-5 mg per lesion, repeated every 1-2 weeks. Topical: Apply thin film to affected area 2-4 times daily.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment. |
| Pediatric use | Topical: Apply sparingly to affected area 1-2 times daily; limit duration and use lowest potency. Intralesional: Not recommended for children. |
| Geriatric use | Use lowest effective dose for shortest duration due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARISTOCORT A (ARISTOCORT A).
| Breastfeeding | Small amounts of triamcinolone acetonide are excreted in human milk. M/P ratio not established. Potential for adrenal suppression in the infant, especially with high maternal doses. The risk to the breastfed infant is considered low with short-term, low-to-moderate doses. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Corticosteroids are associated with an increased risk of cleft palate and intrauterine growth restriction. Second and third trimesters: May cause fetal adrenal suppression and reduced placental weight. Chronic maternal use may lead to premature birth and low birth weight. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to triamcinolone or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Vaccinia or varicella infections","Perioral dermatitis","Rosacea","Acne vulgaris"]
| Precautions | ["Systemic absorption with prolonged use may cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with large areas, occlusive dressings, or pediatric use.","Local adverse reactions: skin atrophy, striae, telangiectasias, purpura, acneiform eruptions, and perioral dermatitis.","Increased risk of infections or exacerbation of existing infections due to immunosuppression.","May mask signs of infection or cause false-negative skin tests.","Pediatric patients may be more susceptible to systemic toxicity and growth retardation.","Use caution on face, intertriginous areas, and over large body surface areas."] |
| Food/Dietary | No known food interactions for topical triamcinolone acetonide. Oral triamcinolone may be taken with food to reduce GI upset. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal monitoring includes ultrasound for growth and placental assessment. In late pregnancy, monitor for fetal adrenal suppression (e.g., abnormal fetal heart rate patterns). |
| Fertility Effects | High-dose corticosteroids may suppress gonadotropin secretion, leading to menstrual irregularities and transient infertility. No direct evidence for permanent fertility impairment with Aristocort A. |
| Clinical Pearls | ARISTOCORT A (triamcinolone acetonide) is a potent topical corticosteroid. Avoid prolonged use on face, groin, or axillae due to risk of atrophy. Use no more than 2 weeks continuously. Do not use with occlusive dressings unless directed. Monitor for adrenal suppression if used over large areas (>20% BSA). |
| Patient Advice | Apply a thin layer to affected skin only, avoiding healthy skin. · Do not cover with bandages or wraps unless instructed by your doctor. · Wash hands after application unless treating hands. · Do not use on broken skin, infections, or near eyes/mouth. · Stop use and contact doctor if irritation occurs or no improvement after 2 weeks. |